Introduction
============

Vitamin A deficiency is a major public health problem. It is most prevalent in young children and pregnant women in low-income countries, especially in Africa and South-East Asia.[@b1] Clinical vitamin A deficiency can manifest as xerophthalmia, blindness and enhanced susceptibility to infections especially measles.[@b2]

Vitamin A supplementation in children aged 6--59 months substantially reduces mortality[@b3] [@b4]; these effects are apparent for deaths due to diarrhoea and measles but not respiratory infections or malaria.[@b3] [@b5] However, the effect of vitamin A supplementation in children younger than 6 months is less clear. Trials of supplementation of 25 000 international units (IU) vitamin A linked to each of the first three doses of diphtheria--tetanus--pertussis immunisations demonstrated no significant effects on early or late infant mortality.[@b6] Early studies from Guinea Bissau suggested that there may be interaction with the season of birth with higher mortality occurring in the rainy season in neonates who were supplemented with vitamin A.[@b7] [@b8] Findings from two trials in Guinea Bissau also suggested increased mortality among girls, but not among boys, in the second half of infancy following neonatal vitamin A supplementation.[@b7] [@b9] However, a recent meta-analysis involving all trials to date indicated that there is no differential effect of neonatal vitamin A supplementation in boys and girls.[@b10]

A recent Cochrane review reported that vitamin A supplementation in women of reproductive age has no significant effect on maternal or infant outcomes.[@b11] This review included our recently reported findings from the Ghana ObaapaVitA cluster-randomised trial of the impact of weekly low-dose (25 000 IU) vitamin A supplementation given to women of reproductive age, which suggested no beneficial effect on the survival of their babies.[@b12] However, there have been no reports of the effect of vitamin A supplementation in women of reproductive age on cause-specific infant mortality or on mortality in early and late infancy. These outcomes were not included in our initial publication due to space limitations.

This paper reports the results of planned (a priori) analyses of the effect of vitamin A supplementation in women of reproductive age on cause- and age-specific infant mortality in the ObaapaVitA trial. We hypothesised that vitamin A supplementation would have significant effects on all three groups (neonatal, early infant and late infant mortality). In addition, because of the recent interest in potential differential effects, we also assessed effects by sex and season.

Methods
=======

Methods are reported in detail elsewhere,[@b12] and the full protocol is available online (at <http://www.lshtm.ac.uk/eph/nphir/research/obaapavita/obaapavita_trial_protocol.pdf>). In brief, all women aged 15--45 years living in seven, predominantly rural, districts in the Brong Ahafo region of Ghana, who were able to give informed consent and who planned to live in the trial area for at least 3 months were eligible for enrolment. Enrolment started in December 2000 and continued throughout the trial; fieldworkers recruited eligible women who migrated into their areas and girls who became fifteen. The trial ended in September 2008, with data collection continuing through October 2008. Verbal postmortems (VPMs) to ascertain cause of death were implemented for all infant deaths from June 2003. Analyses in this paper are therefore based on all live births that took place to study participants between June 2003 and September 2008.

There are two distinct seasons in the study area. October--March is the dry season with high temperatures (mean 30°C) and low rainfall (mean 100 mm). April--September is the rainy season with lower temperatures (mean 26°C) and high rainfall (mean 1270 mm).[@b13]

Intervention
------------

Women were randomised, according to their cluster of residence, to receive either weekly vitamin capsules, containing 25 000 IU (7500 μg) of vitamin A in soybean oil in a dark red opaque soft gel, or identical-looking placebo capsules containing only soybean oil. The vitamin A dose was selected to deliver the recommended dietary allowance while being safe during pregnancy.[@b14] [@b15] The capsules were manufactured by Accucaps Industries Limited, Windsor, Ontario, Canada; the vitamin A was donated by Roche. Women were visited at home every 4 weeks, and given four capsules to be taken over the next 4 weeks. Adherence was supported by an extensive Information, Education and Communication programme, based on formative research conducted before the trial began.[@b16]

Randomisation and blinding
--------------------------

The trial area was divided into clusters of compounds, with fieldworkers responsible for a fieldwork area (FWA) of four contiguous clusters, visiting women in one cluster per week over a 4-weekly cycle. There were a total of 272 FWAs and 1086 clusters. Randomisation was by cluster with two clusters in each FWA allocated to vitamin A and two to placebo to ensure geographic matching of vitamin A and control groups. A computer-generated randomisation list was prepared for the capsule manufacturers by an independent statistician. The capsules were packaged in labelled jars, for each cluster for each week of the trial. No trial personnel (participants, careproviders, data collectors, data analysts, investigators) had access to the randomisation list or to any information that would allow them to deduce or change the cluster allocation.

Data collection
---------------

Fieldworkers collected data during 4-weekly home visits on pregnancies, births, deaths, migrations, socio-demographic characteristics of pregnant women and number of capsules taken since the last visit. From June 2003, field supervisors conducted VPMs with close relatives or friends for all deaths reported among infants born to trial women; these included an open history, plus questions on signs, symptoms and the illness that lead to death. Standard WHO VPM tools and methods were used.[@b17] The methods have been presented and validated in earlier papers.[@b18; @b19; @b20] VPMs were reviewed by two experienced doctors, who independently assigned a single primary cause of death using identical tools. If the coders disagreed, the form was independently reviewed by a third doctor and a consensus coding accepted if two of the three agreed. If there was no consensus, the three coders met to determine whether they could reach agreement. The cause of death classification system had six major categories: congenital abnormalities, prematurity, birth asphyxia, infection (subdivided into neonatal, diarrhoea, pneumonia, malaria, measles, other), other specific cause of death and unexplained cause of death.

Sample size
-----------

Sample size for the trial was determined by the rarest outcome, pregnancy-related mortality, to allow for the detection of a reduction of 33% in pregnancy-related mortality in the vitamin A arm, with 90% power and at 5% significance, and allowing for a 10% design effect. The sample size of 62 000 infants was also sufficient to detect at least a 15% effect of vitamin A supplementation on neonatal, early infant and late infant mortality.

Statistical methods
-------------------

Stata V.10.0 was used for all analyses. Infant mortality (deaths from 0 to 11 months of age), early infant mortality (deaths from 1 to 5 months of age) and late infant mortality (deaths from 6 to 11 months of age) were all expressed per 1000 infant-years of follow-up. Neonatal mortality (\<1 month) was expressed per 1000 live births. Intention-to-treat analyses compared treatment groups using logistic regression for neonatal mortality and Cox regression for infant mortality. Random-effects regression (for logistic regression) or robust standard errors (for Cox regression) were used to take account of the clustered design. The proportional hazards assumption for all Cox regressions was assessed using visual inspection of the Nelson--Aalen log cumulative hazard curves. Interaction between vitamin A supplementation and season or gender was examined using the likelihood ratio test (when using logistic regression) or the Wald test (when using Cox regression).

Intention to treat was by cluster of residence. As previously described,[@b12] we accounted for the fact that vitamin A stores require some time to become replete or depleted by excluding the first 6 months of follow-up after recruitment or after any change of treatment group for the same reasons, and regarding women as belonging to their pre-move group for a period of 2 months after changing group. Infants were considered as belonging to the treatment arm of the mother at the time of delivery.

Trial monitoring and ethical approval
-------------------------------------

The conduct of the trial was overseen by Trial Steering and Data Monitoring and Ethics Committees. It was approved by the ethics committees of the Ghana Health Service and the London School of Hygiene and Tropical Medicine and registered with <http://clinicaltrials.gov> (identifier NCT00211341). Full informed consent was obtained from all trial participants.

Results
=======

Participant flow
----------------

The trial profile is shown in [figure 1](#fig1){ref-type="fig"}. One thousand and eighty-six clusters (542 placebo, 544 vitamin A) in 272 FWAs were randomised. Recruitment, withdrawals and migration patterns were similar in the vitamin A and placebo arms, as were socio-demographic characteristics ([table 1](#tbl1){ref-type="table"}). There were a total of 62 662 live births to 50 422 women of reproductive age in the trial from 1 June 2003 to 30 September 2008 with 52 574 infant-years of follow-up and 3268 infant deaths ([figure 1](#fig1){ref-type="fig"}). For babies born before 31 October 2007, follow-up to 1 year was 86%. Data collection for the trial ended on 31 October 2008, and 90% of the babies born after 31 October 2007 were seen in the last month of data collection or had died before then.

![Profile of trial and subjects included in analysis of all live births from 1 June 2003 to 30 September 2008.](bmjopen-2011-000658fig1){#fig1}

###### 

Comparability of vitamin A and placebo groups, all live births from 1 June 2003 to 30 September 2008

  Characteristic                          Placebo, n (%[\*](#table-fn1){ref-type="table-fn"})   Vitamin A, n (%[\*](#table-fn1){ref-type="table-fn"})
  --------------------------------------- ----------------------------------------------------- -------------------------------------------------------
  Live births in study population (n)     31 164 (100)                                          31 498 (100)
  Age group at the birth outcome, years                                                         
   \<20                                   2404 (8)                                              2536 (8)
   20--24                                 7645 (25)                                             7747 (25)
   25--29                                 8866 (28)                                             8993 (29)
   30--34                                 6848 (22)                                             6818 (22)
   35--39                                 3784 (12)                                             3752 (12)
   ≥40                                    1617 (5)                                              1652 (5)
  Previous live births (n)                                                                      
   0                                      3463 (11)                                             3628 (12)
   1                                      6032 (19)                                             6061 (19)
   2                                      5812 (19)                                             5719 (18)
   3                                      4628 (15)                                             4888 (15)
   4                                      3664 (12)                                             3714 (12)
   5+                                     7217 (23)                                             7179 (23)
   Not known                              348 (1)                                               309 (1)
  Highest educational level                                                                     
   None                                   12 142 (39)                                           12 280 (39)
   Primary school                         5812 (19)                                             5865 (19)
   Secondary school                       12 515 (40)                                           12 636 (40)
   Technical college or university        262 (1)                                               281 (1)
   Not known                              433 (1)                                               436 (1)
  Religion                                                                                      
   Christian                              20 663 (66)                                           20 721 (66)
   Muslim                                 7428 (24)                                             7594 (24)
   Traditional African                    1718 (6)                                              1803 (6)
   Other                                  939 (3)                                               961 (3)
   Not known                              416 (1)                                               419 (1)
  Ethnic group                                                                                  
   Akan                                   13 361 (43)                                           13 693 (43)
   Other                                  17 392 (56)                                           17 386 (55)
   Missing                                411 (1)                                               419 (1)
  Wealth quintiles                                                                              
   1st (poorest)                          8039 (26)                                             8339 (26)
   2nd                                    6743 (22)                                             6666 (21)
   3rd                                    5668 (18)                                             5768 (18)
   4th                                    5177 (17)                                             5171 (16)
   5th (richest)                          4618 (15)                                             4670 (15)
   Not known                              919 (3)                                               884 (3)

Percentages may not add up to 100 due to rounding.

Age at death
------------

Overall, 58.9% (1925/3268) of the deaths occurred in the neonatal period, 21.3% (699/3268) occurred in early infancy (1--5 months) and 19.7% (644/3268) occurred in late infancy (6--11 months) ([table 2](#tbl2){ref-type="table"}). Mortality was comparable for the vitamin A and placebo groups during the neonatal period and in early and late infancy ([table 3](#tbl3){ref-type="table"}).

###### 

Mortality by age and sex for infants born from 1 June 2003 to 30 September 2008

                                                 Overall   Males[\*](#table-fn2){ref-type="table-fn"}   Females[\*](#table-fn2){ref-type="table-fn"}
  ---------------------------------------------- --------- -------------------------------------------- ----------------------------------------------
  Neonatal deaths                                                                                       
   Live births (n)                               62 662    31 631                                       30 980
   Total neonatal deaths                         1925      1113                                         790
   Total neonatal deaths/1000 live births        30.72     35.19                                        25.50
   OR (95% CI)                                   --        1.00                                         0.72 (0.65 to 0.79)
   p Value                                       --        --                                           \<0.0001
  Infant deaths 1--5 months                                                                             
   Infant years of follow-up 1--5 months         23 660    11 886                                       11 772
   Total 1--5 months deaths                      699       362                                          334
   Total 1--5 months deaths/1000 infant-years    29.54     30.46                                        28.37
   HR (95% CI)                                   --        1.00                                         0.93 (0.80 to 1.08)
   p Value                                       --        --                                           0.35
  Infant deaths 6--11 months                                                                            
   Infant years of follow-up 6--11 months        24 094    12 087                                       12 005
   Total 6--11 months deaths                     644       352                                          292
   Total 6--11 months deaths/1000 infant-years   26.73     29.12                                        24.32
   HR (95% CI)                                   --        1.00                                         0.84 (0.72 to 0.98)
   p Value                                       --        --                                           0.02

Sex of baby unknown in 51 of 62 662 infants.

###### 

Effect of maternal weekly vitamin A supplementation on infant deaths by age and sex; intention-to-treat analyses, all live births from 1 June 2003 to 30 September 2008 (n=62 662)

                                                              Both sexes combined   Males[\*](#table-fn3){ref-type="table-fn"}   Females[\*](#table-fn3){ref-type="table-fn"}                                  
  ----------------------------------------------------------- --------------------- -------------------------------------------- ---------------------------------------------- --------------------- -------- ---------------------
  Neonatal deaths                                                                                                                                                                                              
   Live births (n)                                            31 164                31 498                                       15 777                                         15 854                15 357   15 623
   Total neonatal deaths                                      984                   941                                          589                                            524                   382      408
   Total neonatal deaths/1000 infant-years                    31.57                 29.87                                        37.33                                          33.05                 24.87    26.12
   Adjusted OR[†](#table-fn4){ref-type="table-fn"} (95% CI)   1.00                  0.95 (0.86 to 1.04)                          1.00                                           0.88 (0.78 to 1.00)   1.00     1.05 (0.91 to 1.22)
   p Value                                                    --                    0.26                                         --                                             0.05                  --       0.49
  Infant deaths 1--5 months                                                                                                                                                                                    
   Infant years of follow-up 1--5 months                      11 796                11 936                                       5921                                           5965                  5839     5934
   Total 1--5 months deaths                                   341                   358                                          166                                            196                   174      160
   Total 1--5 months deaths/1000 infant-years                 28.91                 29.99                                        28.04                                          32.86                 29.80    26.97
   Adjusted HR[†](#table-fn4){ref-type="table-fn"} (95% CI)   1.00                  1.04 (0.88 to 1.22)                          1.00                                           1.17 (0.95 to 1.45)   1.00     0.91 (0.72 to 1.14)
   p Value                                                    --                    0.65                                         --                                             0.15                  --       0.39
  Infant deaths 6--11 months                                                                                                                                                                                   
   Infant years of follow-up 6--11 months                     12 004                12 161                                       6022                                           6065                  5945     6060
   Total 6--11 months deaths                                  321                   323                                          170                                            182                   151      141
   Total 6--11 months deaths/1000 infant-years                26.74                 26.56                                        28.23                                          30.01                 25.40    23.27
   Adjusted HR[†](#table-fn4){ref-type="table-fn"} (95% CI)   1.00                  0.99 (0.84 to 1.18)                          1.00                                           1.06 (0.85 to 1.33)   1.00     0.92 (0.73 to 1.16)
   p Value                                                    --                    0.94                                         --                                             0.59                  --       0.46

p Value for interaction between vitamin A and sex for neonatal deaths =0.06 (Likelihood ratio statistic =3.48).

p Value for interaction between vitamin A and sex for infant deaths 1--5 months =0.10 (Wald statistic =2.75).

p Value for interaction between vitamin A and sex for infant deaths 6--11 months =0.33 (Wald statistic =0.96).

Sex of baby unknown in 51 of 62 662 infants.

Adjusted for clustering by ObaapaVitA cluster of residence.

Cause of death
--------------

A suitable respondent was found for the administration of 3129 VPMs out of the total 3268 deaths (95.7%). Coders were able to assign a cause for 2589 of these deaths (82.7%). Causes of death were markedly different in the neonatal ([table 4](#tbl4){ref-type="table"}) and postneonatal periods (1--11 months) ([table 5](#tbl5){ref-type="table"}). Asphyxia was coded as the most common cause of neonatal death (37.0%; 568/1536), followed by infection (28.8%; 442/1536) and prematurity (18.3%; 281/1536). In contrast, infection was coded as the cause of 94.2% (992/1053) of the postneonatal deaths; 30% (298/992) of these infection deaths were due to pneumonia, 22.9% (228/992) to malaria, 14.1% (140/992) to diarrhoea, 0.6% (6/992) to measles and 32.3% (320/992) were due to other infection (meningitis, tetanus, HIV/AIDS or infection with an unknown cause).

###### 

Effect of weekly vitamin A supplementation on neonatal deaths by cause of death; intention-to-treat analyses, all live births from 1 June 2003 to 30 September 2008

                                                               Placebo   Vitamin A
  ------------------------------------------------------------ --------- ---------------------
  All live births (n)                                          31 164    31 498
  Total neonatal deaths                                        984       941
  Infection                                                              
   Infection-specific deaths (n)                               218       224
   Infection-specific deaths/1000 live births                  7.00      7.11
   Adjusted OR[\*](#table-fn5){ref-type="table-fn"} (95% CI)   1.00      1.02 (0.84 to 1.23)
   p Value                                                     --        0.86
  Prematurity                                                            
   Prematurity-specific deaths (n)                             149       132
   Prematurity-specific deaths/1000 live births                4.78      4.19
   Adjusted OR[\*](#table-fn5){ref-type="table-fn"} (95% CI)   1.00      0.88 (0.68 to 1.14)
   p Value                                                     --        0.33
  Asphyxia                                                               
   Asphyxia-specific deaths (n)                                284       284
   Asphyxia-specific deaths/1000 live births                   9.11      9.02
   Adjusted OR[\*](#table-fn5){ref-type="table-fn"} (95% CI)   1.00      0.99 (0.83 to 1.19)
   p Value                                                     --        0.95
  Other deaths[†](#table-fn6){ref-type="table-fn"}                       
   Other deaths (n)                                            128       117
   Other specific deaths/1000 live births                      4.11      3.71
   Adjusted OR[\*](#table-fn5){ref-type="table-fn"} (95% CI)   1.00      0.89 (0.69 to 1.17)
   p Value                                                     --        0.41
  Unexplained                                                            
   Unexplained deaths (n)                                      175       156
   Unexplained deaths/1000 live births                         5.62      4.95
   Adjusted OR[\*](#table-fn5){ref-type="table-fn"} (95% CI)   1.00      0.88 (0.71 to 1.10)
   p Value                                                     --        0.26
  Cause of death not ascertained                                         
   Unascertained deaths (n)                                    30        28
   Unascertained deaths/1000 live births                       0.96      0.89
   Adjusted OR[\*](#table-fn5){ref-type="table-fn"} (95% CI)   1.00      0.92 (0.55 to 1.55)
   p Value                                                     --        0.76

Adjusted for clustering by ObaapaVitA cluster of residence.

Includes congenital abnormality, accident or injury, malignant tumours and neonatal jaundice.

###### 

Effect of weekly vitamin A supplementation on postneonatal deaths by cause of death; intention-to-treat analyses, all live births from 1 June 2003 to 30 September 2008

                                                                 Placebo   Vitamin A
  -------------------------------------------------------------- --------- ---------------------
  Infant-years of follow-up                                      23 800    24 097
  Total postneonatal deaths                                      662       681
  Infection                                                                
   Infection-specific deaths (n)                                 479       503
   Infection-specific deaths/1000 child-years                    20.13     20.87
   Adjusted HR[\*](#table-fn7){ref-type="table-fn"} (95% CI)     1.00      1.04 (0.90 to 1.19)
   p Value                                                       --        0.61
    Pneumonia                                                              
     Pneumonia-specific deaths (n)                               152       146
     Pneumonia-specific deaths/1000 child-years                  6.39      6.06
     Adjusted HR[\*](#table-fn7){ref-type="table-fn"} (95% CI)   1.00      0.95 (0.75 to 1.21)
     p Value                                                     --        0.67
    Malaria                                                                
     Malaria-specific deaths (n)                                 115       113
     Malaria-specific deaths/1000 child-years                    4.83      4.69
     Adjusted HR[\*](#table-fn7){ref-type="table-fn"} (95% CI)   1.00      0.97 (0.74 to 1.27)
     p Value                                                     --        0.83
    Diarrhoea                                                              
     Diarrhoea-specific deaths (n)                               60        70
     Diarrhoea-specific deaths/1000 child-years                  2.52      2.90
     Adjusted HR[\*](#table-fn7){ref-type="table-fn"} (95% CI)   1.00      1.15 (0.82 to 1.62)
     p Value                                                     --        0.42
    Measles                                                                
     Measles-specific deaths (n)                                 4         2
     Measles-specific deaths/1000 child-years                    0.17      0.08
     Adjusted HR[\*](#table-fn7){ref-type="table-fn"} (95% CI)   1.00      0.49 (0.09 to 2.69)
     p Value                                                     --        0.41
    Other infection[†](#table-fn8){ref-type="table-fn"}                    
     Other infection deaths (n)                                  148       172
     Other infection-specific deaths/1000 child-years            6.22      7.14
     Adjusted HR[\*](#table-fn7){ref-type="table-fn"} (95% CI)   1.00      1.15 (0.91 to 1.45)
     p Value                                                     --        0.24
  Other deaths[‡](#table-fn9){ref-type="table-fn"}                         
   Other deaths (n)                                              42        29
   Other deaths/1000 child-years                                 1.76      1.20
   Adjusted HR[\*](#table-fn7){ref-type="table-fn"} (95% CI)     1.00      0.68 (0.42 to 1.10)
   p Value                                                       --        0.12
  Unexplained                                                              
   Unexplained deaths (n)                                        106       103
   Unexplained deaths/1000 child years                           4.45      4.27
   Adjusted HR[\*](#table-fn7){ref-type="table-fn"} (95% CI)     1.00      0.96 (0.72 to 1.27)
   p Value                                                       --        0.78
  Cause of death not ascertained                                           
   Unascertained deaths (n)                                      35        46
   Unascertained deaths/1000 child years                         1.47      1.91
   Adjusted HR[\*](#table-fn7){ref-type="table-fn"} (95% CI)     1.00      1.30 (0.84 to 2.00)
   p Value                                                       --        0.24

Adjusted for clustering by ObaapaVitA cluster of residence.

Includes meningitis, tetanus, HIV/AIDS or infection with an unknown cause.

Includes congenital abnormality, accident or injury and malignant tumours.

The distributions of both neonatal and postneonatal causes of death were similar in the placebo and vitamin A groups ([tables 4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"}). There was no marked impact of vitamin A supplementation on any specific cause of mortality, either in the neonatal period ([table 4](#tbl4){ref-type="table"}) or in the postneonatal period ([table 5](#tbl5){ref-type="table"}). The overall HR for infection-specific infant mortality was 1.03 (95% CI 0.92 to 1.16).

Sex
---

Mortality rates were considerably lower for females than males during the neonatal period and late infancy ([table 2](#tbl2){ref-type="table"}). Mortality was also lower in females than males in the early infant period, but this difference was marginal and non-significant. Mortality rates were similar for the vitamin A and placebo groups for both males and females in the neonatal period and early and late infancy. There was also no evidence of modification of the effect of vitamin A supplementation on infant mortality by sex (Wald statistic =0.07, p=0.80).

Season
------

There was no obvious seasonality in mortality rates ([figure 2](#fig2){ref-type="fig"}). Fifty-three per cent (1729/3268) of infant deaths occurred in the rainy season (April--September) and 47% (1539/3268) in the dry season (October--March). Mortality rates were similar in both (HR 0.99 (95% CI 0.92 to 1.06), p=0.67), and there was no impact of vitamin A supplementation on infant deaths in either the rainy (HR 0.98 (95% CI 0.89 to 1.08), p=0.68) or the dry season (HR 0.97 (95% CI 0.87 to 1.08), p=0.56). There was also no evidence of modification of the effect of vitamin A supplementation on infant mortality by season (Wald statistic =0.03, p=0.86).

![Births and infant mortality per 1000 person-years, by calendar month.](bmjopen-2011-000658fig2){#fig2}

Discussion
==========

This large-scale community-based trial provides the largest analysis of cause of infant deaths from Africa to date. Our analyses indicate that weekly vitamin A supplementation in women of reproductive age has no beneficial or deleterious effect on the causes of death in their babies of age 6 or 12 months in rural Ghana.

We identified no other published studies of the effect of vitamin A supplementation in women of reproductive age on cause-specific infant mortality. In particular, no cause-specific data have been reported from the other two trials of maternal vitamin A supplementation in Nepal[@b21] and Bangladesh.[@b22] [@b23] Studies of maternal multiple micronutrient supplementation have also not reported effects on cause-specific infant mortality.[@b24] [@b25] The biological action of vitamin A and previous evidence from childhood vitamin A trials[@b5] [@b26] led us to postulate a priori that vitamin A may have an effect on deaths due to infant infection. However, we found no effect of vitamin A on deaths due to infant infections in our study population. It was also possible that vitamin A could have had an effect on deaths due to prematurity-related complications (eg, bronchopulmonary dysplasia, necrotising enterocolitis, intraventricular haemorrhage) as vitamin A has effects on epithelial integrity, cellular differentiation and foetal surfactant synthesis.[@b2] [@b27] However, we found no impact of vitamin A supplementation in women of reproductive age on prematurity-specific neonatal mortality.

The absence of an impact on early or late infant survival concurs with the findings of trials of maternal vitamin A supplementation from Nepal[@b21] and Bangladesh[@b22] [@b23] and a pooled meta-analysis of the effects of maternal multiple micronutrient supplements.[@b24] [@b25] The results also concur with those of our main paper, which reported no effects of vitamin A supplementation in women of reproductive age on maternal mortality and stillbirths.[@b12] However, none of these trials presented data separately for males and females. We recorded lower mortality rates in females than males throughout infancy and markedly so during the neonatal period and late infancy. We found no evidence of any differential effect of vitamin A supplementation in boys or girls, or by season. This is in contrast to the recent Guinea Bissau trials which indicated that there may be an interaction between neonatal vitamin A supplementation and childhood immunisations by age, sex and season.[@b7] [@b9]

There were some limitations to our trial. There was no direct observation of capsule taking; however, adherence was supported by an extensive Information, Education and Communication strategy, and we estimated that on average 75% of women both received and took all four capsules every month.[@b12] We also used VPMs and physician coders to assign cause of death, and it was not possible to use health facility records or postmortem examinations to verify the cause of death. Misclassification is common in VPM studies, but this can be minimised when broad categories such as 'infection', 'prematurity' and 'asphyxia' are used.[@b17] [@b19] Our VPM tools were also validated in similar study populations, and acceptable sensitivity and specificity were reported in comparison to a gold standard.[@b17] [@b18] [@b20] In addition, our study was prospective and population based. All resident women in the trial districts and their babies were enrolled, and loss to follow-up was low, even in women with babies who had died.

Our findings have important implications for policy and program development. They indicate that vitamin A supplementation in women of reproductive age will not reduce infection-specific infant mortality, has no influence on any of the other causes of death in their infants and is not an effective strategy to improve neonatal or infant survival. It also appears that vitamin A supplementation in women of reproductive age has no role in reducing overall or cause-specific infant mortality in child survival programs. We also failed to demonstrate any harm from vitamin A supplementation in infant males or females in our study population. These findings add to the ongoing debate about the safety of vitamin A supplementation and whether vitamin A supplementation may have differential effects on mortality in boys and girls in early and late infancy.
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